Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...